Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Dec 15, 2016	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	95,223	$380.09	591,348
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	10,023	$467.53	591,569
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	11,916	$466.58	601,592
Dec 13, 2018	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Bona fide gift	118,993	--	602,594
Dec 16, 2008	YANCOPOULOS GEORGE Director, EVP, CSO, & Pres Regn Res Labs	Director, EVP, CSO, & Pres Regn Res Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	32,946	$16.42	603,157
Nov 02, 2015	YANCOPOULOS GEORGE Director, President and CSO	Director, President and CSO	Form 4	Bona fide gift	43,348	--	612,936
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	7,068	$465.45	613,508
Mar 09, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	96,736	$30.63	614,535
Dec 31, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	620,270	--	620,270
Dec 03, 2009	YANCOPOULOS GEORGE Director, EVP CSO & Pres Regn Res Labs	Director, EVP CSO & Pres Regn Res Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	22,397	$19.29	620,375

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media